Both anti-PD-1 and anti-CTLA-4 immunotherapies are administered intravenously (i.v.)and have been shown to induce anti-tumor responses in patients with cancers, including melanoma, non-small cell lung cancer, and renal cell carcinomas. Here, CTLA4 is linked to melanoma.